However, encouragingly, our data show that, in an albeit limited number of ex vivo cultures, CLL cells were sensitive to talazoparib cytotoxicity independent of their p53, ATM or HRR status, confirming that PARP is a therapeutic target in CLL. The gene discussed is ATM; the disease is B-cell chronic lymphocytic leukemia.